Perspective Therapeutics, Inc. (CATX)

US — Healthcare Sector

Peers: LUNG LUCD NPCE LGMK ZVSA UNCY TORO

Automate Your Wheel Strategy on CATX

With Tiblio's Option Bot, you can configure your own wheel strategy including CATX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol CATX
Rev/Share 0.0046
Book/Share 3.5791
PB 1.031
Debt/Equity 0.0072
CurrentRatio 15.0899
ROIC -0.2733

MktCap 274001090.0
FreeCF/Share -1.5147
PFCF -2.4367
PE -2.8849
Debt/Assets 0.0062
DivYield 0
ROE -0.3248

Rating B-
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 4
D/E Score 4

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Initiation	CATX	H.C. Wainwright	--	Buy	--	$10	March 13, 2025
Initiation	CATX	Scotiabank	--	Sector Outperform	--	$15	March 7, 2025
Initiation	CATX	Wedbush	--	Outperform	--	$25	Oct. 1, 2024
Initiation	CATX	Truist	--	Buy	--	$21	Sept. 25, 2024

News

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

CATX
Published: July 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2025 taking place October 17 to 21, 2025 in Berlin, Germany. ESMO plans to release further details for regular abstracts on October 13, 2025.

image for news Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

CATX
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced that updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois.

image for news Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

CATX
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company's [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation as detailed below at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. ASCO plans to release further details for regular abstracts on May 22, 2025 at 5:00 PM EDT.

image for news Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Perspective Therapeutics to Present at Upcoming March Investor Conferences

CATX
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

image for news Perspective Therapeutics to Present at Upcoming March Investor Conferences

About Perspective Therapeutics, Inc. (CATX)

IPO Date 2005-11-10
Website https://www.perspectivetherapeutics.com
Industry Medical - Devices
CEO Johan M. Spoor
Employees 138

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.